1)Costa RA, Jorge R, Calucci D et al:Intravitreal bevacizumab for choroidal neovascularization caused by AMD(IBeNA Study):results of phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 47:4569-4578, 2006
2)Avery RL, Pearlman J, Pieramici DJ et al:Intravitreal bevacizumab(Avastin)in the treatment of proliferative diabetic retinopathy. Ophthalmology 113:1695-1705, 2006
3)Wakabayashi T, Oshima Y, Sakaguchi H et al:Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 115:1571-1580, 2008
4)Haritoglou C, Kook D, Neubauer A et al:Intravitreal bevacizumab(Avastin)therapy for persistent diffuse diabetic macular edema. Retina 26:999-1005, 2006
5)Amano S, Kuroki M, Tolentino M et al:Requirement for vascular endothelial growth factor in wound-related corneal neovascularization. Invest Ophthalmol Vis Sci 39:18-22, 1998
6)Philipp W, Speicher L, Humpel C:Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 41:2514-2522, 2000
7)Cursienfen C, Rummelt C, Kuchle M:Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor α, and transforming growth factor β1 in human corneas with neovascularization. Cornea 19:526-533, 2000
8)Destafeno JJ, Kim T:Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 125:834-836, 2007
9)Kim SW, Ha BJ, Kim EK et al:The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 115:e33-e38, 2008
10)Uy HS, Chan PS, Ang RE:Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome. Cornea 27:70-73, 2007
11)Wu PC, Kuo HK, Tai MH et al:Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium. Cornea 28:103-104, 2009
12)Shapiro LA, Farkas TG:Lipid keratopathy following corneal hydrops. Arch Ophthalmol 95:456-458, 1977
13)Roth SI, Stock EL, Siel JM et al:Pathogenesis of experimental lipid keratopathy. Invest Ophthalmol Vis Sci 29:1544-1551, 1988
14)Bear JC, Foster CS:Corneal laser photocoagulation for treatment of neovascularization. Efficacy of 577nm yellow dye laser. Ophthalmology 99:173-179, 1992
15)Brooks BJ, Ambati BK, Marcus DM et al:Photodynamic therapy for corneal neovascularisation and lipid degeneration. Br J Ophthalmol 88:840, 2004
16)Bock F, Onderka J, Rummelt C et al:Safety profile of topical VEGF neutralization at the cornea. Invest Ophthalmol Vis Sci 50:2095-2102, 2009